Grunewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Alava E, Kovar H, et al. Ewing sarcoma. Nat Rev Dis Prim. 2018;4:5.

PubMed  Google Scholar 

Riggi N, Suva ML, Stamenkovic I. Ewing’s sarcoma. N. Engl J Med. 2021;384:154–64.

CAS  PubMed  Google Scholar 

Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, et al. Microsatellites as EWS/FLI response elements in Ewing’s sarcoma. Proc Natl Acad Sci USA. 2008;105:10149–54.

CAS  PubMed  PubMed Central  Google Scholar 

Boulay G, Volorio A, Iyer S, Broye LC, Stamenkovic I, Riggi N, et al. Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies. Genes Dev. 2018;32:1008–19.

CAS  PubMed  PubMed Central  Google Scholar 

Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O, et al. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nat Commun. 2019;10:4128.

PubMed  PubMed Central  Google Scholar 

Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schonegger A, Datlinger P, et al. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 2015;10:1082–95.

CAS  PubMed  PubMed Central  Google Scholar 

Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005;363:1–14.

CAS  PubMed  Google Scholar 

Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells. J Clin Invest. 1997;99:239–47.

CAS  PubMed  PubMed Central  Google Scholar 

Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing’s sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049–54.

CAS  PubMed  Google Scholar 

Flores G, Grohar PJ. One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma. J Bone Oncol. 2021;31:100404.

PubMed  PubMed Central  Google Scholar 

Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA. 2009;106:5324–9.

CAS  PubMed  PubMed Central  Google Scholar 

Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, et al. EWS/ETS-driven Ewing Sarcoma requires BET Bromodomain proteins. Cancer Res. 2018;78:4760–73.

CAS  PubMed  Google Scholar 

Lin L, Huang M, Shi X, Mayakonda A, Hu K, Jiang YY, et al. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1. Nucleic Acids Res. 2019;47:1255–67.

CAS  PubMed  Google Scholar 

Sanchez-Molina S, Figuerola-Bou E, Blanco E, Sanchez-Jimenez M, Taboas P, Gomez S, et al. RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. Sci Adv. 2020;6:eaba3058.

Schmidt O, Nehls N, Prexler C, von Heyking K, Groll T, Pardon K, et al. Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis. J Exp Clin Cancer Res. 2021;40:322.

CAS  PubMed  PubMed Central  Google Scholar 

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, et al. Therapeutic targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 engages the endoplasmic reticulum stress response. Mol Cancer Ther. 2018;17:1902–16.

CAS  PubMed  PubMed Central  Google Scholar 

Orphanides G, Wu WH, Lane WS, Hampsey M, Reinberg D. The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins. Nature 1999;400:284–8.

CAS  PubMed  Google Scholar 

Formosa T, Winston F. The role of FACT in managing chromatin: disruption, assembly, or repair? Nucleic Acids Res. 2020;48:11929–41.

CAS  PubMed  PubMed Central  Google Scholar 

Kim M, Neznanov N, Wilfong CD, Fleyshman DI, Purmal AA, Haderski G, et al. Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas. Cancer Res. 2016;76:6620–30.

CAS  PubMed  PubMed Central  Google Scholar 

Somers K, Kosciolek A, Bongers A, El-Ayoubi A, Karsa M, Mayoh C, et al. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. Int J Cancer. 2019;146:1902–16.

Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol. 2017;19:186–96.

CAS  PubMed  Google Scholar 

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med. 2015;7:312ra176.

PubMed  PubMed Central  Google Scholar 

Mo J, Liu F, Sun X, Huang H, Tan K, Zhao X, et al. Inhibition of the FACT complex targets aberrant hedgehog signaling and overcomes resistance to smoothened antagonists. Cancer Res. 2021;81:3105–20.

CAS  PubMed  Google Scholar 

Wang J, Sui Y, Li Q, Zhao Y, Dong X, Yang J, et al. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137. Cell Death Dis. 2020;11:1029.

PubMed  PubMed Central  Google Scholar 

Savola S, Klami A, Myllykangas S, Manara C, Scotlandi K, Picci P, et al. High expression of Complement Component 5 (C5) at tumor site associates with superior survival in Ewing’s Sarcoma family of tumour patients. ISRN Oncol. 2011;2011:168712.

PubMed  PubMed Central  Google Scholar 

Postel-Vinay S, Veron AS, Tirode F, Pierron G, Reynaud S, Kovar H, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet. 2012;44:323–7.

CAS  PubMed  Google Scholar 

Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol. 2009;27:2209–16.

CAS  PubMed  Google Scholar 

Liu D, Sartor MA, Nader GA, Pistilli EE, Tanton L, Lilly C, et al. Microarray analysis reveals novel features of the muscle aging process in men and women. J Gerontol A Biol Sci Med Sci. 2013;68:1035–44.

PubMed  PubMed Central  Google Scholar 

Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 2013;23:1797–809.

PubMed  PubMed Central  Google Scholar 

Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suva ML, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26:668–81.

CAS  PubMed  PubMed Central  Google Scholar 

Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779–84.

CAS  PubMed  PubMed Central  Google Scholar 

Wang S, Hwang EE, Guha R, O’Neill AF, Melong N, Veinotte CJ, et al. High-throughput chemical screening identifies focal adhesion Kinase and Aurora Kinase B Inhibition as a synergistic treatment combination in Ewing Sarcoma. Clin Cancer Res. 2019;25:4552–66.

CAS  PubMed  PubMed Central  Google Scholar 

Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, et al. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res. 2008;6:1937–45.

CAS  PubMed  Google Scholar 

Chang HW, Valieva ME, Safina A, Chereji RV, Wang J, Kulaeva OI, et al. Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins. Sci Adv. 2018;4:eaav2131.

CAS  PubMed  PubMed Central  Google Scholar 

Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016;13:521–7.

CAS  PubMed  PubMed Central  Google Scholar 

Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle. 2008;7:250–6.

CAS  PubMed  Google Scholar 

Adane B, Alexe G, Seong BKA, Lu D, Hwang EE, Hnisz D, et al. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Cancer Cell. 2021;39:827–44.e10.

CAS  PubMed  PubMed Central  Google Scholar 

Sen N, Cross AM, Lorenzi PL, Khan J, Gryder BE, Kim S, et al. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis. Mol Carcinog. 2018;57:1342–57.

CAS  PubMed  PubMed Central  Google Scholar 

Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, et al. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: role in tumor growth and immune evasion. J Natl Cancer Inst. 2019;111:970–82.

PubMed  PubMed Central  Google Scholar 

Fukuma M, Okita H, Hata J, Umezawa A. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 2003;22:1–9.

CAS  PubMed  Google Scholar 

Kirschner A, Thiede M, Grunewald TG, Alba Rubio R, Richter GH, Kirchner T, et al. Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo. Oncoimmunology 2017;6:e1273301.

PubMed  PubMed Central  Google Scholar 

Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20:97.

CAS